InsidersTradesSigma
Follow the Tvardi Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €16.6m. The latest transaction was reported on 5 August 2025 (J). Among the most active insiders: HALL WALLACE L JR. All data is accessible without an account.
Analysts rate Tvardi Therapeutics, Inc. Buy (bullish), based on 8 analysts. Average price target: US$8.50.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Tvardi Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It specializes in the discovery and commercialization of targeted therapies.